Safety of gefitinib in non-small cell lung cancer treatment (Q38841473)

6 September 2017

1 reference

title

Safety of gefitinib in non-small cell lung cancer treatment (English)

1 reference

6 September 2017

author

Emily Han-Chung Hsiue

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Jih-Hsiang Lee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Chia-Chi Lin

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

English

0 references

publication date

21 May 2016

1 reference

Expert Opinion on Drug Safety

6 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

993-1000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

ERBB receptors and cancer: the complexity of targeted inhibitors

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Mechanisms of cutaneous toxicities to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Paronychia Induced by Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Rociletinib in EGFR-mutated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

10.1080/14740338.2016.1192605

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json